K
0JQ2
vs
S&P 500
S&P 500
Over the past 12 months, 0JQ2 has underperformed S&P 500, delivering a return of -83% compared to the S&P 500's +27% growth.
Stocks Performance
0JQ2 vs S&P 500
Performance Gap
0JQ2 vs S&P 500
Performance By Year
0JQ2 vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
KALA BIO Inc
Glance View
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
